{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:42:57Z","timestamp":1794584577886,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00818-6","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:13:05Z","timestamp":1745431985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of heterologous intranasal iNCOVACC\u00ae vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial"],"prefix":"10.1038","volume":"5","author":[{"given":"Venkateshwar Rao","family":"Akula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Suresh","family":"Bhate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar S.","family":"Gillurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra Singh","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-8191","authenticated-orcid":false,"given":"Anil Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaraj","family":"K. K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2477-4580","authenticated-orcid":false,"given":"Krishna Mohan","family":"Vadrevu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BBV154 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunda","family":"Ganneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth Reddy","family":"Chiteti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivas","family":"Kataram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raches","family":"Ella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai. D","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"818_CR1","doi-asserted-by":"publisher","unstructured":"Ayoub, H. H. et al. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob. Epidemiol. https:\/\/doi.org\/10.1016\/j.gloepi.2021.100068 (2021).","DOI":"10.1016\/j.gloepi.2021.100068"},{"key":"818_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","volume":"114","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int. J. Infect. Dis. 114, 252\u2013260 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"818_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/17476348.2022.2057299","volume":"16","author":"SWX Ong","year":"2022","unstructured":"Ong, S. W. X., Chia, T. & Young, B. E. SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. Expert Rev. Respir. Med. 16, 499\u2013502 (2022).","journal-title":"Expert Rev. Respir. Med."},{"key":"818_CR4","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. 384, 1885\u20131898 (2021).","journal-title":"N. Engl. J. Med."},{"key":"818_CR5","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433 e2413 (2022).","journal-title":"Cell"},{"key":"818_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30340-5","volume":"13","author":"F Zuo","year":"2022","unstructured":"Zuo, F. et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat. Commun. 13, 2670 (2022).","journal-title":"Nat. Commun."},{"key":"818_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521\u2013529 (2022).","journal-title":"Lancet"},{"key":"818_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1126\/science.abg9857","volume":"373","author":"FE Lund","year":"2021","unstructured":"Lund, F. E. & Randall, T. D. Scent of a vaccine. Science 373, 397\u2013399 (2021).","journal-title":"Science"},{"key":"818_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"JX Li","year":"2022","unstructured":"Li, J. X. et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir. Med. 10, 739\u2013748 (2022).","journal-title":"Lancet Respir. Med."},{"key":"818_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184 e113 (2020).","journal-title":"Cell"},{"key":"818_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109400","volume":"36","author":"TL Bricker","year":"2021","unstructured":"Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021).","journal-title":"Cell Rep."},{"key":"818_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100230","volume":"2","author":"AO Hassan","year":"2021","unstructured":"Hassan, A. O. et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep. Med. 2, 100230 (2021).","journal-title":"Cell Rep. Med."},{"key":"818_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00717-8","volume":"8","author":"C Singh","year":"2023","unstructured":"Singh, C. et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae). npj Vaccines 8, 125 (2023).","journal-title":"npj Vaccines"},{"key":"818_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102298","volume":"24","author":"B Ganneru","year":"2021","unstructured":"Ganneru, B. et al. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience 24, 102298 (2021).","journal-title":"iScience"},{"key":"818_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/ijmr.IJMR_663_20","volume":"151","author":"PD Yadav","year":"2020","unstructured":"Yadav, P. D. et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J. Med. Res. 151, 200\u2013209 (2020).","journal-title":"Indian J. Med. Res."},{"key":"818_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e04658","volume":"6","author":"R Sardar","year":"2020","unstructured":"Sardar, R., Satish, D., Birla, S. & Gupta, D. Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies. Heliyon 6, e04658 (2020).","journal-title":"Heliyon"},{"key":"818_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","volume":"7","author":"Y Watanabe","year":"2021","unstructured":"Watanabe, Y. et al. Native-like SARS-CoV-2 Spike glycoprotein expressed by ChAdOx1 nCoV-19\/AZD1222 vaccine. ACS Cent. Sci. 7, 594\u2013602 (2021).","journal-title":"ACS Cent. Sci."},{"key":"818_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect. Dis. 21, 950\u2013961 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"818_CR19","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","volume":"398","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet 398, 2173\u20132184 (2021).","journal-title":"Lancet"},{"key":"818_CR20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/j.1541-0420.2008.00990.x","volume":"64","author":"A Agresti","year":"2008","unstructured":"Agresti, A., Bini, M., Bertaccini, B. & Ryu, E. Simultaneous confidence intervals for comparing binomial parameters. Biometrics 64, 1270\u20131275 (2008).","journal-title":"Biometrics"},{"key":"818_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16097-3","volume":"12","author":"KM Vadrevu","year":"2022","unstructured":"Vadrevu, K. M. et al. Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. Sci. Rep. 12, 12038 (2022).","journal-title":"Sci. Rep."},{"key":"818_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40592-4","volume":"14","author":"H Hornsby","year":"2023","unstructured":"Hornsby, H. et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nat. Commun. 14, 5065 (2023).","journal-title":"Nat. Commun."},{"key":"818_CR23","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","volume":"3","author":"MA Croyle","year":"2008","unstructured":"Croyle, M. A. et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3, e3548 (2008).","journal-title":"PLoS ONE"},{"key":"818_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"818_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"818_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324, 951\u2013960 (2020).","journal-title":"JAMA"},{"key":"818_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103788","volume":"75","author":"L Azzi","year":"2022","unstructured":"Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine 75, 103788 (2022).","journal-title":"EBioMedicine"},{"key":"818_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4853","volume":"7","author":"J Tang","year":"2022","unstructured":"Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol. 7, eadd4853 (2022).","journal-title":"Sci. Immunol."},{"key":"818_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","volume":"398","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856\u2013869 (2021).","journal-title":"Lancet"},{"key":"818_CR30","doi-asserted-by":"crossref","unstructured":"Sapkota, B. et al. Heterologous prime-boost strategies for COVID-19 vaccines. J. Travel Med. 29, taab191 (2022).","DOI":"10.1093\/jtm\/taab191"},{"key":"818_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1555","volume":"13","author":"Zijun Wang","year":"2021","unstructured":"Wang, Zijun et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).","journal-title":"Sci. Transl. Med."},{"key":"818_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00356-x","volume":"6","author":"SA Mendonca","year":"2021","unstructured":"Mendonca, S. A., Lorincz, R., Boucher, P. & Curiel, D. T. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 6, 97 (2021).","journal-title":"NPJ Vaccines"},{"key":"818_CR33","doi-asserted-by":"publisher","unstructured":"Sarkar, A. et al. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum. Vaccin. Immunother. https:\/\/doi.org\/10.1080\/21645515.2023.2212568 (2023).","DOI":"10.1080\/21645515.2023.2212568"},{"key":"818_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"818_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2022","unstructured":"Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599\u2013601 (2022). Feb 10.","journal-title":"N. Engl. J. Med."},{"key":"818_CR36","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.abq0203","volume":"377","author":"JE Bowen","year":"2022","unstructured":"Bowen, J. E. et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 377, 890\u2013894 (2022).","journal-title":"Science"},{"key":"818_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32298-w","volume":"13","author":"L Bellusci","year":"2022","unstructured":"Bellusci, L. et al. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Nat. Commun. 13, 4617 (2022).","journal-title":"Nat. Commun."},{"key":"818_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMc2206576","volume":"387","author":"NP Hachmann","year":"2022","unstructured":"Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86\u201388 (2022).","journal-title":"N. Engl. J. Med."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00818-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00818-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00818-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:13:07Z","timestamp":1745431987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00818-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00818-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest. K.M.V., B.G., S.R.C., K.S., R.E., and S.P. are employees of Bharat Biotech, with no stock options or incentives. A.V.R., A.R.B., C.S.G., J.S.K., A.P.S., C.S., A.K.P., S.K.K., and S.K.R. were principal investigators representing the study sites. Authors from Bharat Biotech and Principal Investigators had final responsibility for the decision to submit for publication. The study sponsor had no role in biostatistical analysis and in writing the report, which was done by the Contract Research Organization (CRO). CRO is responsible for unblinding. K.M.V. and S.R.C. from Bharat Biotech, and the contract research organization had full access to the data in the study, after unblinding.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}